Secondary Logo

Institutional members access full text with Ovid®

Cell-based immunotherapy in gynecologic malignancies

Schaar, Brucea; Krishnan, Venkatesha; Tallapragada, Supreetia; Chanana, Anitaa; Dorigo, Oliverb

Current Opinion in Obstetrics and Gynecology: February 2019 - Volume 31 - Issue 1 - p 43–48
doi: 10.1097/GCO.0000000000000518
GYNECOLOGIC CANCER: Edited by Gottfried E. Konecny
Buy
SDC

Purpose of review To provide an update on cell-based immunotherapies in solid tumors particularly in gynecological cancers.

Recent findings Improvements have been made in engineering T cells to overcome the immunosuppressive environment in ovarian cancer. Significant efforts are underway to create ‘off the shelf’ cell therapies which leverage natural killer (NK) cells and would not rely on engineering a patient's T cells.

Summary Efforts to target solid tumors using cell-based therapies are expanding into cell types other than T cells (NK cells and macrophages) which may have a lower risk of significant side effects and higher efficacy in solid tumors than chimeric antigen receptor T cells.

aDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology

bDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Women's Cancer Center, Stanford University School of Medicine, Stanford, California, USA

Correspondence to Oliver Dorigo, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Women's Cancer Center, Stanford University School of Medicine, Stanford, California, USA. E-mail: odorigo@stanford.edu

Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.